Abstract

Avinza is a once-daily, extended-release oral morphine preparation. It has a pharmacokinetic profile that exhibits less peak-to-trough fluctuations in plasma concentration whilst providing analgesia statistically identical to that produced by MS Contin (controlled-release morphine sulfate), Oxycontin (oxycodone HCl controlled-release) and six doses of oral morphine sulfate administered every 4 h. Avinza improves quality of sleep by several measures but interestingly gives the best sleep improvement when given in the morning rather than at night. It causes the same side effects of other opioids: constipation, nausea, vomiting, somnolence and mood swings. Doses of 30 - 60 mg/day have been shown to be well tolerated by patients with osteoarthritis (even in the elderly), who have failed other medications.

Links

Publisher Full Text

Authors

Caldwell JR

Institution

Radiant Research, Daytona Beach, FL 32114, USA.

Source

Expert opinion on pharmacotherapy 5:2 2004 Feb pg 469-72

MeSH

Administration, Oral
Clinical Trials as Topic
Delayed-Action Preparations
Double-Blind Method
Humans
Morphine
Multicenter Studies as Topic
Pain

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

14996642